Evidence map›Paper›PMID 40860811›Full record

ArticleFrontiers in oncology2025

Define a good prognosis of

Feng Wang, Li Lin, Zhongkang Li, Lei Qin, Shuai Zhang, Xueqing Hu, Yunbo Zhao, Yingying Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Feng Wang *Department of Gastrointestinal Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Li Lin *Department of Oncology Center, Peking University International Hospital, Beijing, China.
Zhongkang Li *Geneplus-Beijing, Beijing, China.
Lei QinGeneplus-Beijing, Beijing, China.
Shuai ZhangDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Beijing, China.
Xueqing HuDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Beijing, China.
Yunbo ZhaoDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Beijing, China.
Yingying HuangDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Heterogeneity of colorectal cancer (CRC) leads to significant differences in Overall Survival (OS). Methods: The clinical characteristics, mutational characteristics, and survival data of CRC patients were obtained for Results: 11 datasets with 4028 patient data were screened for this study. The most common variant was frameshift, which occurred in codon 659-mutated of exon 9, including Conclusions: In CRC, we found that the G1 cohort had the best prognosis, and patients with

Indexed as

cbioportal databasecolorectal cancer (CRC)mutation analysisprognosticRNF43-mutated

Identifiers

PMID40860811
PMCPMC12371537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.